US20150335653A1 - Pharmaceutical compositions of linezolid - Google Patents
Pharmaceutical compositions of linezolid Download PDFInfo
- Publication number
- US20150335653A1 US20150335653A1 US14/818,866 US201514818866A US2015335653A1 US 20150335653 A1 US20150335653 A1 US 20150335653A1 US 201514818866 A US201514818866 A US 201514818866A US 2015335653 A1 US2015335653 A1 US 2015335653A1
- Authority
- US
- United States
- Prior art keywords
- linezolid
- pharmaceutical composition
- form iii
- stable pharmaceutical
- mixtures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Definitions
- Linezolid is a synthetic antibacterial agent. Chemically, it is (S)—N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide.
- the empirical formula is C 16 H 20 FN 3 O 4 . Its molecular weight is 337.35.
- Linezolid is used in the treatment of vancomycin-resistant enterococcus faecium infections; nosocomial pneumonia; complicated skin and skin structure infections including diabetic foot infections, without concomitant osteomyelitis; uncomplicated skin and skin structure infections and community acquired pneumonia.
- Linezolid is sold in the U.S. under the brand name(s) of ZYVOX® I.V. Injection, ZYVOX Tablets, and ZYVOX for Oral Suspension. Tablets were given two to three times a day.
- Linezolid and its salts are described in U.S. Pat. No. 5,688,792. Crystalline form I and II are known polymorphs of Linezolid. Crystalline form I of linezolid was described by J. Med. Chem. 39(3), 673-679, 1996.
- U.S. Pat. No. 6,559,305 discloses a crystalline linezolid form II.
- WO2007/102082 assigned to Glenmark Pharmaceuticals Ltd discloses compositions of Linezolid crystalline Form II containing lactose-based water soluble excipient.
- U.S. Publication no. 2007/0104785 discloses a manufacture of the solid oral dosage form of linezolid Form III. It describes a gelling potential of linezolid Form III which affects the reproducibility of dissolution.
- the manufacturing of the dosage form with reproducible dissolution profile was achieved by using effervescent couple (or) by incorporating water insoluble polymers (or) by adding clays in the dosage form (or) combinations thereof.
- WO 2010/026597 assigned to Hetero discloses a multiparticulate composition which requires forming a core in the form of beadlet or pellet manufactured by extrusion and spheronization method, where the core comprises linezolid form III, one or more binders, and one or more disintegrants. Both processes require either special material or equipment which are not desirable for commercial production.
- a first aspect of the present invention provides stable pharmaceutical composition
- Another aspect of the present invention provides stable pharmaceutical composition
- Another aspect of the present invention is to provide a stable pharmaceutical composition containing one or more combination of excipients having different functional properties such as sodium carboxy methyl cellulose, calcium carboxy methyl cellulose, di calcium phosphate, sodium starch glycolate, lactose, microcrystalline cellulose, polacrilin potassium, polyvinyl pyrollidone, hydroxy propyl methyl cellulose, alginic acid, sodium alginate, magnesium stearate, sodium stearyl fumarate, colloidal silicon dioxide suitable for stable compositions without polymorphic form conversion.
- the present invention also provides process for preparing stable pharmaceutical composition comprising linezolid form III, polacrilin potassium as disintegrant and at least one pharmaceutically acceptable excipient, using wet granulation, dry granulation, spray granulation or direct compression to develop a solid dosage form without polymorphic form conversion.
- Another aspect of the present invention provides process for preparing stable pharmaceutical composition comprising linezolid form III and at least one pharmaceutically acceptable excipient by wet granulation using about 10% w/w of water (based on total weight of the core tablet) as granulating solvent, wherein the composition retains more than 80% linezolid form III.
- Another aspect of the present invention is directed to method of preparing a solid pharmaceutical composition by admixing linezolid from III with pharmaceutically acceptable excipients to provide a mixture and directly compressing the mixture.
- Another aspect of the present invention is directed to method of preparing a solid pharmaceutical composition comprising linezolid form III by dry granulation.
- linezolid form III is dry granulated with lactose monohydrate, hydroxypropylmethyl cellulose and/or starch, polacrilin potassium, magnesium stearate to develop a stable formulation without polymorphic form conversion.
- Preferred aspect of the present invention involves dry granulating linezolid form III with polacrilin potassium as disintegrant with one or more pharmaceutically acceptable excipients to develop a stable formulation without polymorphic form conversion.
- Another aspect of the present invention provides process for preparing stable pharmaceutical composition
- a pharmaceutical composition comprising linezolid form III, polacrilin potassium as disintegrant, microcrystalline cellulose as diluent and optionally one or more pharmaceutically acceptable excipients by dry granulation, wherein the composition retains linezolid in its crystalline form III.
- composition or “formulation” as used here synonymously for solid oral dosage forms such as tablets, capsules, sachets etc.
- Stable composition means a composition containing linezolid having more than 80% crystallinity in Form III, preferably more than 85% crystallinity in Form III, and more preferably more than 95% crystallinity in Form III determined by an instrumental test, for example, by XRD, IR, TGA, etc. during manufacturing process and/or under a storage condition (shelf live).
- the present aim of the invention is to develop a stable linezolid formulation using various combinations of excipients without converting polymorphic form of the active ingredient in the dosage form.
- compatibility studies with various excipients were done to develop a stable formulation that retains its polymorphic form.
- Excipient selection depends on various factors, such as, the choice of active ingredient percentage, the objectives of the tablet formulation development and method of manufacture. The foremost property of each excipient is that it must possess compatibility with active ingredient without affecting its polymorphic form
- Another aspect of the present invention is suitable combinations of excipients having different functional properties such as sodium carboxy methyl cellulose, calcium carboxy methyl cellulose, di calcium phosphate, sodium starch glycolate, lactose monohydrate, lactose impalable, polacrilin potassium, polyvinyl pyrollidone, hydroxy propyl methyl cellulose, alginic acid, sodium alginate, magnesium stearate, sodium stearyl fumarate, colloidal silicon dioxide, are studied to develop a stable formulation without polymorphic form conversion.
- stable pharmaceutical composition comprising linezolid with hydroxypropylmethyl cellulose as a binder and polacrilin potassium as a disintegrant, and optionally one or more additional excipients.
- a pharmaceutical composition of the present invention may also comprise one or more other excipients such as a diluent, a glidant and a lubricant.
- the pharmaceutical composition according to the present invention are oral solid dosage forms such as tablet, a caplet, a pellet, a capsule, granules, a pill, powder or a sachet.
- the pharmaceutical composition is in the form of a tablet.
- linezolid used in the oral solid pharmaceutical composition is crystalline form III.
- the pharmaceutically acceptable excipients in accordance with the invention include at least one binder and/or at least one disintegrant, and/or at least one diluent and/or at least one lubricant and/or at least one stabiliser.
- the binder includes hydroxypropyl methylcellulose (hydroxypropylmethyl cellulose), polyvinylpyrrolidone k-30, hydroxypropyl cellulose (low-substituted), starch or mixtures thereof and more preferable binder is hydroxypropylmethyl cellulose and/or starch.
- the disintegrant include sodium starch glycolate, croscarmellose sodium, polacrilin potassium and cross-linked polyvinyl pyrrolidone or mixtures thereof and more preferable disintegrant is polacrilin potassium.
- the diluent include mannitol, sorbitol, xylitol, lactose monohydrate, microcrystalline cellulose, light magnesium carbonate, dicalcium phosphate, tribasic calcium phosphate, calcium sulphate or mixture thereof, and more preferable diluent is lactose monohydrate and/or light magnesium carbonate.
- the lubricant includes magnesium stearate, zinc stearate, calcium stearate, sodium stearyl fumarate and stearic acid or mixtures thereof and more preferable lubricant is magnesium stearate.
- the glidant includes colloidal anhydrous silica.
- ingredients such as stabilizers and antiadherants, conventionally used for pharmaceutical formulations may also be included in the present formulation.
- the tablets were manufactured using wet granulation, direct compression, dry granulation (slugging) to develop a stable formulation without polymorphic form conversion.
- Another aspect of the present invention provides wet granulation process with different concentrations of water such as 10% w/w, 20% w/w, 30% w/w as granulation solvent for preparation of the core tablet.
- Another aspect of the present invention is directed to method of preparing a solid pharmaceutical composition
- a solid pharmaceutical composition comprising admixing linezolid from III with pharmaceutically acceptable excipients and compressing the mixture in to tablets.
- a process for preparing stable pharmaceutical composition which comprises mixing linezolid from III, hydroxypropylmethyl cellulose as a binder and polacrilin potassium as a disintegrant, and optionally one or more additional excipients and compressing in to tablet.
- the pharmaceutical compositions prepared according to process of the invention are oral solid dosage forms such as tablet, a caplet, a pellet, a capsule, granules, a pill, powder or a sachet.
- the tablet may be optionally coated with a coating agent.
- the film coating is non functional and provides good appearance to the final dosage form.
- the preferred embodiment of the invention suitable for forming linezolid tablet comprising in parts by weight from about 60% to about 90% linezolid, from about 1% to about 30% lactose monohydrate, from about 0.3% to about 20% hydroxypropylmethyl cellulose and/or starch, from about 0.2% to about 8% polacrilin potassium, from about 0.5% to about 5% magnesium stearate.
- additional excipient/s such as diluents, binders, disintegrants, lubricants, glidants, fillers or mixtures thereof may be used.
- Linezolid, lactose monohydrate, hydroxypropylmethyl cellulose, polacrilin potassium and magnesium stearate are sifted through suitable mesh and blended.
- the dry mix is granulated by slugging method.
- the formed slug mass was milled and passed through suitable screen.
- the blend is pre-lubricated and lubricated with lactose monohydrate, silica colloidal anhydrous, polacrilin potassium, magnesium stearate and compressed into a tablet using appropriate tooling or the granules were filled into capsules/sachets.
- Example -5 Example -6 S. No Ingredients Mg/tablet Mg/tablet Intragranular 1 Linezolid (Form III) 600 600 2 Lactose monohydrate 25 25 3 Starch 1500 85 85 4 Hydroxypropylmethyl cellulose 3 3 5 Magnesium stearate 4 4 Extra granular 6 Starch 1500 60 60 7 Silica colloidal anhydrous 10 10 8 Polacrilin potassium 42 — 9 Croscarmellose sodium — 42 10 Magnesium stearate 4 4 TOTAL WEIGHT 833 833 The Manufacturing Process: The dry granules were made with the procedure described in the example 1. The lubricated blend was compressed into tablets using appropriate tooling.
- Tablets were prepared exactly to example 17 by wet granulation using 20% w/w and 30% w/w of water as granulation solvent and subjected to XRD studies.
- FIG. 1 XRD diffractogram of the linezolid form III.
- FIG. 2 XRD diffractogram of the linezolid form III pharmaceutical compositions prepared by wet granulation using the concentration of 10% w/w of water.
- FIG. 3 XRD diffractogram of the linezolid form III pharmaceutical compositions prepared by wet granulation with 20% w/w of water.
- FIG. 4 XRD diffractogram of the linezolid form III pharmaceutical compositions prepared by wet granulation with 30% w/w of water.
- FIG. 5 XRD diffractogram of the linezolid form III at room temperature.
- FIG. 6 XRD diffractogram of the linezolid form III pharmaceutical composition prepared by dry granulation at 40° C./75% RH (relative humidity) for 1 month.
- FIG. 7 XRD diffractogram of the linezolid form III pharmaceutical composition prepared by dry granulation at 40° C./75% RH for 2 months.
- FIG. 8 XRD diffractogram of the linezolid form III pharmaceutical composition prepared by dry granulation at 40° C./75% RH for 3 months.
- FIG. 9 XRD diffractogram of the linezolid form III pharmaceutical composition prepared by dry granulation at 25° C./60% RH for 3 months.
- FIG. 10 XRD diffractogram of the linezolid form III pharmaceutical composition prepared by dry granulation at 60° C. for 1 month.
- Dry granulation (slugging) process retains the crystalline form III of linezolid in the composition.
- Dry granulating linezolid form III with polacrilin potassium as disintegrant retains its polymorphic form in the dosage form as compared to other superdisintegrants such as croscarmellose sodium.
- Dry granulating linezolid form III with lactose monohydrate, hydroxypropylmethyl cellulose and/or starch, polacrilin potassium and magnesium stearate enhances the stability by retaining its polymorphic form.
- Dry granulation is better than wet granulation to provide a stable formulation with out polymorphic form conversion.
Abstract
The present invention relates to stable pharmaceutical compositions comprising linezolid crystalline Form III with one or more pharmaceutically acceptable excipients, wherein the composition retains linezolid in its original crystalline form.
Description
- This application is a continuation of U.S. application Ser. No. 13/813,459 filed on Jan. 31, 2013 which is a 371 of PCT/IN2011/000583 filed on Aug. 29, 2011, which claims the benefit of priority to Indian Application No. 2557/CHE2010, filed on Sep. 2, 2010, the contents of which are incorporated by reference here in.
- Linezolid is a synthetic antibacterial agent. Chemically, it is (S)—N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide. The empirical formula is C16H20FN3O4. Its molecular weight is 337.35.
- Linezolid is used in the treatment of vancomycin-resistant enterococcus faecium infections; nosocomial pneumonia; complicated skin and skin structure infections including diabetic foot infections, without concomitant osteomyelitis; uncomplicated skin and skin structure infections and community acquired pneumonia.
- Linezolid is sold in the U.S. under the brand name(s) of ZYVOX® I.V. Injection, ZYVOX Tablets, and ZYVOX for Oral Suspension. Tablets were given two to three times a day.
- Linezolid and its salts are described in U.S. Pat. No. 5,688,792. Crystalline form I and II are known polymorphs of Linezolid. Crystalline form I of linezolid was described by J. Med. Chem. 39(3), 673-679, 1996.
- U.S. Pat. No. 6,559,305 discloses a crystalline linezolid form II.
- WO2007/102082 assigned to Glenmark Pharmaceuticals Ltd discloses compositions of Linezolid crystalline Form II containing lactose-based water soluble excipient.
- In the recent years, a new polymorph of linezolid, namely form III, was discovered and described in U.S. Pat. No. 7,714,128. The crystalline form III was characterized by an x-ray powder diffraction spectrum having peaks expressed as 20 at about 7.6, 9.6, 13.6, 14.9, 18.2, 18.9, 21.2, 22.3, 25.6, 26.9, 27.9 and 29.9 degrees.
- U.S. Publication no. 2007/0104785 discloses a manufacture of the solid oral dosage form of linezolid Form III. It describes a gelling potential of linezolid Form III which affects the reproducibility of dissolution. The manufacturing of the dosage form with reproducible dissolution profile was achieved by using effervescent couple (or) by incorporating water insoluble polymers (or) by adding clays in the dosage form (or) combinations thereof.
- WO 2010/026597 assigned to Hetero discloses a multiparticulate composition which requires forming a core in the form of beadlet or pellet manufactured by extrusion and spheronization method, where the core comprises linezolid form III, one or more binders, and one or more disintegrants. Both processes require either special material or equipment which are not desirable for commercial production.
- There is a need to develop a composition and its process for manufacturing a solid unit dosage form comprising linezolid form III which retains its polymorphic form and stable during manufacturing process and throughout the shelf life.
- A first aspect of the present invention provides stable pharmaceutical composition comprising linezolid crystalline Form III with one or more pharmaceutically acceptable excipients, prepared by dry granulation process, wherein the composition retains linezolid in its original crystalline form.
- Another aspect of the present invention provides stable pharmaceutical composition comprising a therapeutically effective amount of a linezolid form III, polacrilin potassium as disintegrant, hydroxypropylmethyl cellulose as binder and optionally one or more additional excipients, wherein the composition retains linezolid in its crystalline form.
- Another aspect of the present invention is to provide a stable pharmaceutical composition containing one or more combination of excipients having different functional properties such as sodium carboxy methyl cellulose, calcium carboxy methyl cellulose, di calcium phosphate, sodium starch glycolate, lactose, microcrystalline cellulose, polacrilin potassium, polyvinyl pyrollidone, hydroxy propyl methyl cellulose, alginic acid, sodium alginate, magnesium stearate, sodium stearyl fumarate, colloidal silicon dioxide suitable for stable compositions without polymorphic form conversion.
- The present invention also provides process for preparing stable pharmaceutical composition comprising linezolid form III, polacrilin potassium as disintegrant and at least one pharmaceutically acceptable excipient, using wet granulation, dry granulation, spray granulation or direct compression to develop a solid dosage form without polymorphic form conversion.
- Another aspect of the present invention provides process for preparing stable pharmaceutical composition comprising linezolid form III and at least one pharmaceutically acceptable excipient by wet granulation using about 10% w/w of water (based on total weight of the core tablet) as granulating solvent, wherein the composition retains more than 80% linezolid form III.
- Another aspect of the present invention is directed to method of preparing a solid pharmaceutical composition by admixing linezolid from III with pharmaceutically acceptable excipients to provide a mixture and directly compressing the mixture.
- Another aspect of the present invention is directed to method of preparing a solid pharmaceutical composition comprising linezolid form III by dry granulation.
- In another aspect of the present invention linezolid form III is dry granulated with lactose monohydrate, hydroxypropylmethyl cellulose and/or starch, polacrilin potassium, magnesium stearate to develop a stable formulation without polymorphic form conversion.
- Preferred aspect of the present invention involves dry granulating linezolid form III with polacrilin potassium as disintegrant with one or more pharmaceutically acceptable excipients to develop a stable formulation without polymorphic form conversion.
- Another aspect of the present invention provides process for preparing stable pharmaceutical composition comprising linezolid form III, polacrilin potassium as disintegrant, microcrystalline cellulose as diluent and optionally one or more pharmaceutically acceptable excipients by dry granulation, wherein the composition retains linezolid in its crystalline form III.
- “Composition” or “formulation” as used here synonymously for solid oral dosage forms such as tablets, capsules, sachets etc.
- Stable composition, according to the present invention means a composition containing linezolid having more than 80% crystallinity in Form III, preferably more than 85% crystallinity in Form III, and more preferably more than 95% crystallinity in Form III determined by an instrumental test, for example, by XRD, IR, TGA, etc. during manufacturing process and/or under a storage condition (shelf live).
- The present aim of the invention is to develop a stable linezolid formulation using various combinations of excipients without converting polymorphic form of the active ingredient in the dosage form.
- According to one aspect of the present invention, compatibility studies with various excipients were done to develop a stable formulation that retains its polymorphic form.
- Excipient selection depends on various factors, such as, the choice of active ingredient percentage, the objectives of the tablet formulation development and method of manufacture. The foremost property of each excipient is that it must possess compatibility with active ingredient without affecting its polymorphic form
- Another aspect of the present invention is suitable combinations of excipients having different functional properties such as sodium carboxy methyl cellulose, calcium carboxy methyl cellulose, di calcium phosphate, sodium starch glycolate, lactose monohydrate, lactose impalable, polacrilin potassium, polyvinyl pyrollidone, hydroxy propyl methyl cellulose, alginic acid, sodium alginate, magnesium stearate, sodium stearyl fumarate, colloidal silicon dioxide, are studied to develop a stable formulation without polymorphic form conversion.
- In another aspect of the present invention, there is provided stable pharmaceutical composition comprising linezolid with hydroxypropylmethyl cellulose as a binder and polacrilin potassium as a disintegrant, and optionally one or more additional excipients.
- A pharmaceutical composition of the present invention may also comprise one or more other excipients such as a diluent, a glidant and a lubricant.
- The pharmaceutical composition according to the present invention are oral solid dosage forms such as tablet, a caplet, a pellet, a capsule, granules, a pill, powder or a sachet. Preferably the pharmaceutical composition is in the form of a tablet.
- Preferably, linezolid used in the oral solid pharmaceutical composition is crystalline form III.
- Preferably, the pharmaceutically acceptable excipients in accordance with the invention include at least one binder and/or at least one disintegrant, and/or at least one diluent and/or at least one lubricant and/or at least one stabiliser.
- Preferably, the binder includes hydroxypropyl methylcellulose (hydroxypropylmethyl cellulose), polyvinylpyrrolidone k-30, hydroxypropyl cellulose (low-substituted), starch or mixtures thereof and more preferable binder is hydroxypropylmethyl cellulose and/or starch.
- Preferably, the disintegrant include sodium starch glycolate, croscarmellose sodium, polacrilin potassium and cross-linked polyvinyl pyrrolidone or mixtures thereof and more preferable disintegrant is polacrilin potassium.
- Preferably, the diluent include mannitol, sorbitol, xylitol, lactose monohydrate, microcrystalline cellulose, light magnesium carbonate, dicalcium phosphate, tribasic calcium phosphate, calcium sulphate or mixture thereof, and more preferable diluent is lactose monohydrate and/or light magnesium carbonate.
- Preferably, the lubricant includes magnesium stearate, zinc stearate, calcium stearate, sodium stearyl fumarate and stearic acid or mixtures thereof and more preferable lubricant is magnesium stearate. Preferably, the glidant includes colloidal anhydrous silica.
- Other ingredients such as stabilizers and antiadherants, conventionally used for pharmaceutical formulations may also be included in the present formulation.
- In another aspect of the present invention, the tablets were manufactured using wet granulation, direct compression, dry granulation (slugging) to develop a stable formulation without polymorphic form conversion.
- Another aspect of the present invention provides wet granulation process with different concentrations of water such as 10% w/w, 20% w/w, 30% w/w as granulation solvent for preparation of the core tablet.
- Wet granulation with about 10% w/w of water (based on total weight of core tablet) is found to be suitable for developing a stable formulation.
- Another aspect of the present invention is directed to method of preparing a solid pharmaceutical composition comprising admixing linezolid from III with pharmaceutically acceptable excipients and compressing the mixture in to tablets.
- In another aspect of the present invention preferably, dry granulation by slugging to develop a stable formulation without polymorphic form conversion of linezolid.
- According to another aspect of the present invention, there is provided a process for preparing stable pharmaceutical composition which comprises mixing linezolid from III, hydroxypropylmethyl cellulose as a binder and polacrilin potassium as a disintegrant, and optionally one or more additional excipients and compressing in to tablet.
- Preferably, the pharmaceutical compositions prepared according to process of the invention are oral solid dosage forms such as tablet, a caplet, a pellet, a capsule, granules, a pill, powder or a sachet.
- The tablet may be optionally coated with a coating agent. The film coating is non functional and provides good appearance to the final dosage form.
- The preferred embodiment of the invention suitable for forming linezolid tablet comprising in parts by weight from about 60% to about 90% linezolid, from about 1% to about 30% lactose monohydrate, from about 0.3% to about 20% hydroxypropylmethyl cellulose and/or starch, from about 0.2% to about 8% polacrilin potassium, from about 0.5% to about 5% magnesium stearate. Optionally additional excipient/s such as diluents, binders, disintegrants, lubricants, glidants, fillers or mixtures thereof may be used.
- The invention is further exemplified with following examples and is not intended to limit the scope of the invention. It is obvious to those skilled in the art to find out the composition for other dosage forms and substitute the equivalent excipients as described in this specification or with the one known to the industry.
-
-
S. No Ingredients Mg/Tablet Intragranular 1 Linezolid (Form III) 600 2 Lactose monohydrate 70 3 Hydroxypropylmethyl cellulose 12 4 Polacrilin potassium 5 5 Magnesium stearate 10 Extragranular Ingredients 6 Lactose monohydrate 140 7 Silica colloidal anhydrous 10 8 Polacrilin potassium 5 9 Magnesium stearate 8 10 Opadry White 03B58895 13.00 11 Purified water qs Total weight 873 - Linezolid, lactose monohydrate, hydroxypropylmethyl cellulose, polacrilin potassium and magnesium stearate are sifted through suitable mesh and blended. The dry mix is granulated by slugging method. The formed slug mass was milled and passed through suitable screen. The blend is pre-lubricated and lubricated with lactose monohydrate, silica colloidal anhydrous, polacrilin potassium, magnesium stearate and compressed into a tablet using appropriate tooling or the granules were filled into capsules/sachets.
-
-
S. No Ingredients Mg/Tablet Intragranular 1 Linezolid (Form III) 600 2 Lactose monohydrate 25 3 Light magnesium carbonate 25 4 Hydroxypropylmethyl cellulose 12 5 Polacrilin potassium 5 6 Magnesium stearate 10 Extragranular Ingredients 7 Lactose monohydrate 145 8 Silica colloidal anhydrous 10 9 Polacrilin potassium 8 10 Magnesium stearate 8 Total weight 848
Brief Manuacturing Process: The dry granules were prepared with the procedure described in the example 1. The lublicated blend was compressed into tablets using appropriate tooling. -
-
S. No Ingredients Mg/Tablet Intragranular 1 Linezolid (Form III) 600 2 Lactose monohydrate 25 3 Light magnesium carbonate 10 4 Hydroxypropylmethyl cellulose 12 5 Magnesium stearate 10 Extragranular Ingredients 6 Lactose monohydrate 165 7 Silica colloidal anhydrous 10 8 Polacrilin potassium 3 9 Magnesium stearate 8 Total weight 843
Brief Manufacturing Process: The dry granules were prepared with the procedure described in the example 1. The lubricated blend was compressed into tablets using appropriate tooling. -
-
S. No Ingredients Mg/Tablet Intragranular 1 Linezolid Form III 600 2 Microcrysatlline cellulose 25 3 Light magnesium carbonate 25 4 Hydroxypropylmethyl cellulose 24 5 Polacrilin potassium 5 6 Magnesium stearate 10 Extragranular Ingredients 7 Microcrysatlline cellulose 135 8 Silica colloidal anhydrous 10 9 Polacrilin potassium 8 10 Magnesium stearate 8 Total weight 850
Brief Manufacturing Process: The dry granules were made with the procedure described in the example 1. The lubricated blend was compressed into tablets using appropriate tooling. -
-
Example -5 Example -6 S. No Ingredients Mg/tablet Mg/tablet Intragranular 1 Linezolid (Form III) 600 600 2 Lactose monohydrate 25 25 3 Starch 1500 85 85 4 Hydroxypropylmethyl cellulose 3 3 5 Magnesium stearate 4 4 Extra granular 6 Starch 1500 60 60 7 Silica colloidal anhydrous 10 10 8 Polacrilin potassium 42 — 9 Croscarmellose sodium — 42 10 Magnesium stearate 4 4 TOTAL WEIGHT 833 833
The Manufacturing Process: The dry granules were made with the procedure described in the example 1. The lubricated blend was compressed into tablets using appropriate tooling. -
-
S. No Ingredients Mg/Tablet Intragranular 1. Linezolid (Form III) 600 2. Lactose monohydrate 110 3. Hydroxypropylmethyl cellulose 3 4. Magnesium stearate 4 5. Water 10% w/w Extragranular Ingredients 6. Lactose monohydrate 60 7. Silica colloidal anhydrous 10 8. Polacrilin potassium 39 9. Magnesium stearate 4 Total weight 830
Brief Manufacturing Process: Intragranular excipients were granulated using 10% w/w of water as granulation solvent to obtain the granules. Granules were dried, lubricated and finally compressed in to tablets. - Tablets were prepared exactly to example 17 by wet granulation using 20% w/w and 30% w/w of water as granulation solvent and subjected to XRD studies.
-
FIG. 1 : XRD diffractogram of the linezolid form III. -
FIG. 2 : XRD diffractogram of the linezolid form III pharmaceutical compositions prepared by wet granulation using the concentration of 10% w/w of water. -
FIG. 3 : XRD diffractogram of the linezolid form III pharmaceutical compositions prepared by wet granulation with 20% w/w of water. -
FIG. 4 : XRD diffractogram of the linezolid form III pharmaceutical compositions prepared by wet granulation with 30% w/w of water. -
FIG. 5 : XRD diffractogram of the linezolid form III at room temperature. -
FIG. 6 : XRD diffractogram of the linezolid form III pharmaceutical composition prepared by dry granulation at 40° C./75% RH (relative humidity) for 1 month. -
FIG. 7 : XRD diffractogram of the linezolid form III pharmaceutical composition prepared by dry granulation at 40° C./75% RH for 2 months. -
FIG. 8 : XRD diffractogram of the linezolid form III pharmaceutical composition prepared by dry granulation at 40° C./75% RH for 3 months. -
FIG. 9 : XRD diffractogram of the linezolid form III pharmaceutical composition prepared by dry granulation at 25° C./60% RH for 3 months. -
FIG. 10 : XRD diffractogram of the linezolid form III pharmaceutical composition prepared by dry granulation at 60° C. for 1 month. -
-
TABLE I Stability results of linezolid form III at room temperature, 25° C./60% RH, 40° C./75% RM and 60° C. in the compositions of examples 1-6 prepared by dry granulation. 25° C./ 40° C./ Examples Interval 60% RH 75% RH 60° C. 1-5 T = 0 Form III Form III Form III T = 1 Month — Form III Form III T = 2 Months — Form III — T = 3 Months Form III Form III — 6 T = 0 85% 85% 85% crystallinity crystallinity crystallinity in Form III in Form III in Form III - The results in table II reveals that the pharmaceutical composition prepared by wet granulation with 20% w/w and 30% w/w of water as granulation solvent undergoes polymorphic form conversion even at room temperature. Surprisingly, dosage form produced by wet granulating with 10% w/w of water as granulation solvent are stable to maintain its crystallinity in Form III.
-
TABLE II Stability results of linezolid form III at room temperature using wet granulation with different concentrations of water (compositions of examples 7-9 prepared by wet granulation). Interval 10% w/w of water 20% w/w of water 30% w/w of water T = 0 100% crystallinity 80% crystallinity 70% crystallinity in Form III in Form III in Form III - The results in table II reveals that the pharmaceutical composition prepared by wet granulation with 20% w/w and 30% w/w of water as granulation solvent undergoes polymorphic form conversion event at room temperature. Surprisingly, dosage form produced by wet granulating with 10% w/w of water as granulation solvent are stable to maintain its crystallinity in Form III.
- The results of the above described experiments demonstrate the following:
- Dry granulation (slugging) process retains the crystalline form III of linezolid in the composition.
- Dry granulating linezolid form III with polacrilin potassium as disintegrant retains its polymorphic form in the dosage form as compared to other superdisintegrants such as croscarmellose sodium.
- Dry granulating linezolid form III with lactose monohydrate, hydroxypropylmethyl cellulose and/or starch, polacrilin potassium and magnesium stearate enhances the stability by retaining its polymorphic form.
- Wet granulating linezolid form III with 10% w/w of water as granulation solvent are stable to maintain its crystallinity in Form III.
- Dry granulation is better than wet granulation to provide a stable formulation with out polymorphic form conversion.
Claims (8)
1. A stable pharmaceutical composition comprising linezolid Form III and polacrilin potassium as disintegrant, prepared by a dry granulation process, wherein the composition retains linezolid in its original Form III crystalline form.
2. The stable pharmaceutical composition of claim 1 , further comprising hydroxypropylmethyl cellulose as a binder.
3. The stable pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable excipient selected from a diluent, a binder, a glidant, a lubricant, a disintegrant, stabilizer, and mixtures thereof.
4. The stable pharmaceutical composition of claim 3 , wherein the binder is selected from hydroxypropylmethyl cellulose, polyvinylpyrrolidone k-30, hydroxypropyl cellulose (low-substituted), starch, and mixtures thereof.
5. The stable pharmaceutical composition of claim 3 , wherein the diluent is selected from mannitol, sorbitol, xylitol, lactose monohydrate, microcrystalline cellulose, magnesium carbonate, dicalcium phosphate, tribasic calcium phosphate, and mixtures thereof.
6. The stable pharmaceutical composition of claim 3 , wherein the lubricant is selected from magnesium stearate, zinc stearate, calcium stearate, sodium stearyl fumarate, stearic acid, and mixtures thereof.
7. The stable pharmaceutical composition of claim 1 , comprising 60% to 90% w/w of linezolid Form III, 1% to 30% w/w of lactose monohydrate, 0.3% to 20% w/w of hydroxypropylmethyl cellulose, 0.2% to 8% w/w of polacrilin potassium, and 0.5% to 5% w/w of magnesium stearate.
8. The stable pharmaceutical composition of claim 1 , in the form of an oral solid dosage forms selected from a tablet, a caplet, a pellet, a capsule, granules, a pill, powder, and a sachet.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/818,866 US20150335653A1 (en) | 2010-09-02 | 2015-08-05 | Pharmaceutical compositions of linezolid |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2557CH2010 | 2010-09-02 | ||
IN2557/CHE/2010 | 2010-09-02 | ||
PCT/IN2011/000583 WO2012029074A2 (en) | 2010-09-02 | 2011-08-29 | Pharmaceutical compositions of linezolid |
US201313813459A | 2013-01-31 | 2013-01-31 | |
US14/818,866 US20150335653A1 (en) | 2010-09-02 | 2015-08-05 | Pharmaceutical compositions of linezolid |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2011/000583 Continuation WO2012029074A2 (en) | 2010-09-02 | 2011-08-29 | Pharmaceutical compositions of linezolid |
US13/813,459 Continuation US9132132B2 (en) | 2010-09-02 | 2011-08-29 | Pharmaceutical compositions of linezolid |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150335653A1 true US20150335653A1 (en) | 2015-11-26 |
Family
ID=45773328
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/813,459 Expired - Fee Related US9132132B2 (en) | 2010-09-02 | 2011-08-29 | Pharmaceutical compositions of linezolid |
US14/818,866 Abandoned US20150335653A1 (en) | 2010-09-02 | 2015-08-05 | Pharmaceutical compositions of linezolid |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/813,459 Expired - Fee Related US9132132B2 (en) | 2010-09-02 | 2011-08-29 | Pharmaceutical compositions of linezolid |
Country Status (3)
Country | Link |
---|---|
US (2) | US9132132B2 (en) |
EP (1) | EP2611799A4 (en) |
WO (1) | WO2012029074A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9132132B2 (en) * | 2010-09-02 | 2015-09-15 | Hetero Research Foundation | Pharmaceutical compositions of linezolid |
US9492459B2 (en) | 2012-08-10 | 2016-11-15 | Indoco Remedies Limited | Pharmaceutical composition of linezolid |
CN104622831B (en) * | 2013-11-06 | 2018-06-22 | 江苏豪森药业集团有限公司 | A kind of oral tablet and preparation method thereof |
CN105055354B (en) * | 2015-09-08 | 2017-11-21 | 深圳万乐药业有限公司 | A kind of Linezolid piece and preparation method thereof |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9132132B2 (en) * | 2010-09-02 | 2015-09-15 | Hetero Research Foundation | Pharmaceutical compositions of linezolid |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
US6444813B2 (en) * | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
US6514529B2 (en) * | 2000-03-22 | 2003-02-04 | Pharmacia & Upjohn Company | Oxazolidinone tablet formulation |
ES2803516T3 (en) * | 2003-10-16 | 2021-01-27 | Symed Labs Ltd | A crystalline form of linezolid |
US20060111350A1 (en) * | 2004-06-29 | 2006-05-25 | Judith Aronhime | Solid forms of linezolid and processes for preparation thereof |
US20060142283A1 (en) * | 2004-06-29 | 2006-06-29 | Judith Aronhime | Crystalline form IV of linezolid |
US7327822B2 (en) | 2005-07-20 | 2008-02-05 | Purdue Research Foundation | Methods, apparatus, and software for reconstructing an image |
JP2009501794A (en) * | 2005-07-20 | 2009-01-22 | テバ ファーマシューティカル インダストリーズ リミティド | Stable pharmaceutical composition comprising linezolid Form IV |
US20070104785A1 (en) | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
EP2033960A3 (en) * | 2007-09-04 | 2009-04-29 | Dipharma Francis S.r.l. | Linezolid crystalline hydrate form and linezolid salts |
WO2010026597A1 (en) | 2008-09-02 | 2010-03-11 | Hetero Research Foundation | Oral dosage forms of linezolid and processes for their preparation |
-
2011
- 2011-08-29 US US13/813,459 patent/US9132132B2/en not_active Expired - Fee Related
- 2011-08-29 EP EP11821221.6A patent/EP2611799A4/en not_active Withdrawn
- 2011-08-29 WO PCT/IN2011/000583 patent/WO2012029074A2/en active Application Filing
-
2015
- 2015-08-05 US US14/818,866 patent/US20150335653A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9132132B2 (en) * | 2010-09-02 | 2015-09-15 | Hetero Research Foundation | Pharmaceutical compositions of linezolid |
Also Published As
Publication number | Publication date |
---|---|
US20130274262A1 (en) | 2013-10-17 |
WO2012029074A3 (en) | 2012-05-10 |
US9132132B2 (en) | 2015-09-15 |
EP2611799A2 (en) | 2013-07-10 |
WO2012029074A2 (en) | 2012-03-08 |
EP2611799A4 (en) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8877238B2 (en) | Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound | |
US20150335653A1 (en) | Pharmaceutical compositions of linezolid | |
US20070104785A1 (en) | Tablets of linezolid form iii and processes for their preparation | |
US20130344146A1 (en) | Dry formulations of aripiprazole | |
JP2014520842A (en) | Capsule formulation containing montelukast and ribocetirizine | |
CA2700844A1 (en) | Stable imatinib compositions | |
US11911509B2 (en) | Pharmaceutical composition comprising Lenvatinib mesylate | |
US20120107397A1 (en) | Pharmaceutical compositions of valsartan | |
WO2010041277A2 (en) | Stable pharmaceutical compositions of montelukast or its salts or solvates or hydrates | |
KR20150138104A (en) | Pharmaceutical preperation containing Bepotastine and Glyceryl Behenate | |
KR20190015329A (en) | A pharmaceutical composition of a dapagliflozin co-crystal | |
US20200155546A1 (en) | Stable cariprazine formulations for oral use | |
US20150182629A1 (en) | Stable compositions of fesoterodine | |
WO2016079687A1 (en) | Oral pharmaceutical composition of teriflunomide | |
US20210060019A1 (en) | Pharmaceutical compositions comprising ibrutinib | |
EP3860606B1 (en) | Pharmaceutical composition comprising lenvatinib esylate or tosylate | |
AU2016268477B2 (en) | Pharmaceutical compositions | |
US20130085145A1 (en) | Imatinib mesilate pharmaceutical tablet | |
US20150224086A1 (en) | Pharmaceutical Formulations of Rufinamide | |
US20150190388A1 (en) | Pharmaceutical composition of moxifloxacin hydrochloride and preparation method | |
US20120177729A1 (en) | Sustained release composition of ranolazine | |
WO2012172413A1 (en) | Pharmaceutical composition comprising a combination of eperisone and diclofenac and process for preparing thereof | |
US9492459B2 (en) | Pharmaceutical composition of linezolid | |
US20230310327A1 (en) | Pharmaceutical compositions comprising ribociclib | |
WO2023096615A2 (en) | A compressed solid oral dosage form comprising pinaverium and medazepam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |